Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Associate Professor from Department of Physiology, China Medical University, Taiwan

Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.

Professional Profile

Education

Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.

Professional Experience

Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.

Research Interests

Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.

Research Skills

Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.

Awards and Honors

Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.

Conclusion

Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.

Publication Top Notes

M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025

2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025

3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025

4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024

5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024

6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2

7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2

GHADEER SUAIFAN | Pharmaceutical Sciences | Best Researcher Award

Prof GHADEER SUAIFAN | Pharmaceutical Sciences | Best Researcher Award

Research Scholar, The University of Jordan, Jordan

Ghadeer A. Suaifan was born in December 1973 and is a Jordanian national. She is fluent in both Arabic and English. Ghadeer holds a PhD and an MPhil in Medicinal Chemistry and Instrumental Analysis from the University of Bath, UK, and a BSc (Honours) in Pharmacy from Petra University, Jordan. She currently serves as a Professor of Medicinal Chemistry and Pharmaceutical Instrumental Analysis at the Faculty of Pharmacy, The University of Jordan. Her research interests span medicinal chemistry, nanotechnology, and public health, with significant contributions in optimizing antidiabetic candidates, cancer treatments, and developing advanced analytical techniques. Ghadeer has published extensively and holds several patents.

Profile

Education🎓

From 2001 to 2004, Ghadeer A. Suaifan pursued a PhD in Medicinal Chemistry and Instrumental Analysis at the Department of Pharmacy and Pharmacology, University of Bath, UK. Prior to this, she completed an MPhil in Medicinal Chemistry and Instrumental Analysis at the same institution from 2000 to 2001. Ghadeer began her academic journey with a BSc (Honours) in Pharmacy from the College of Pharmacy, Petra University, Amman, Jordan, which she completed between 1991 and 1996. Her foundational education was acquired at Al-Room Al-Catholic School in Zarka, Jordan, where she earned her General Secondary Education Certificate from 1988 to 1991.

Experience 🏢

Prof. Ghadeer Suaifan is a distinguished Professor of Medicinal Chemistry and Pharmaceutical Instrumental Analysis at the Faculty of Pharmacy, The University of Jordan, where she has been serving since September 2016. In this role, she leads advanced research and teaching, significantly contributing to the academic and research excellence of the institution. Prior to this, she held the position of Associate Professor from September 2012 to September 2016, during which she focused on enhancing the curriculum and advancing research initiatives in medicinal chemistry and pharmaceutical sciences. From 2005 to 2012, Prof. Suaifan worked as an Assistant Professor at the same faculty, delivering undergraduate and postgraduate courses in pharmaceutical sciences and engaging in significant research activities. Additionally, she served as an Assistant Professor at the Faculty of Pharmacy, Philadelphia University, Amman, Jordan, from 2004 to 2005, where she contributed to the development of pharmaceutical education and research. Prof. Suaifan’s extensive experience and dedication have made her a vital asset to the field of pharmaceutical sciences in Jordan.

Research Interests 🔬

Ghadeer’s research encompasses Medicinal Chemistry and Instrumental Analysis, focusing on optimizing new antidiabetic candidates, elucidating molecular structures, and developing advanced prodrug systems for prostate cancer. Her work extends to Nanotechnology, including biological particle detection, miniaturized instrumentation, and medical diagnostics. She also investigates Public Research, evaluating antibiotic use behaviors and the prevalence of Complementary and Alternative Medicine in Jordan.

Special Awards 🏆

Professor Ghadeer Suaifan has been recognized for her outstanding contributions to research and development. She received the prestigious Ibtikar Award from Mewiin, Kuwait, in 2020. Her dedication to scientific research was further acknowledged with the Samia Mango Award from the Hamdi Mango Center for Scientific Research in Amman, Jordan, in 2018. In 2015, she was honored with the Excellent Oral Presenter Award at the International Conference on Pharmaceutical Sciences (ICPS) held in Dubai. Professor Suaifan’s academic achievements were consistently recognized during her time at the Faculty of Pharmacy, Petra University, where she received University Awards for Best Achievement from 1991 to 1996. In addition to her accolades, she has been a Registered Pharmacist with the Jordanian Pharmacists Association in Amman since January 1996, showcasing her longstanding commitment to the pharmaceutical profession and her continuous contributions to the field.

Publications Top Notes 📚

  1. Magnetic beads-based nanozyme for portable colorimetric biosensing of Helicobacter pylori
    • Authors: Suaifan, G.A.R.Y., Shehadeh, M.B., Darwish, R.M., Alaridah, N., Zourob, M.
    • Year: 2024
    • Journal: Biosensors and Bioelectronics: X, Volume 20, Article 100517
  2. Rapid Colorimetric Quantitative Portable Platform for Detection of Brucella melitensis Based on a Fluorescence Resonance Energy Transfer Assay and Nanomagnetic Particles
    • Authors: Alhogail, S., Chinnappan, R., Suaifan, G.A., Jürgen, P., Zourob, M.M.
    • Year: 2024
    • Journal: ACS Omega, Volume 9, Issue 19, Pages 20997–21005
  3. A cross-sectional study on adult lifestyle habits during the COVID-19 pandemic
    • Authors: Suaifan, G.A.R.Y., Abu-Odeh, A.M., Shehadeh, M.B., Jbara, W.A., Nassar, R.I.
    • Year: 2024
    • Journal: PLoS ONE, Volume 19, Issue 5, Article e0299668
  4. Synthesis, urease inhibitory and anticancer evaluation of glucosamine-sulfonylurea conjugates
    • Authors: Suaifan, G.A.R.Y., Shehadeh, M., Tahboub, D., Gaurav, A., Khan, M.
    • Year: 2024
    • Journal: Medicinal Chemistry Research, Volume 33, Issue 4, Pages 663–676
  5. Glucosamine substituted sulfonylureas: IRS-PI3K-PKC-AKT-GLUT4 insulin signalling pathway intriguing agent
    • Authors: Suaifan, G.A.R.Y., Alkhawaja, B., Shehadeh, M.B., Hor Kuan, C., Okechukwu, P.N.
    • Year: 2024
    • Journal: RSC Medicinal Chemistry, Volume 15, Issue 2, Pages 695–703
  6. Development of Rapid Aptamer-Based Screening Assay for the Detection of Covid-19 Variants
    • Authors: Aloraij, Y.M., Suaifan, G.A.R.Y., Shibl, A., Al-Kattan, K., Zourob, M.M.
    • Year: 2023
    • Journal: ACS Omega, Volume 8, Issue 36, Pages 32877–32883
  7. Medicinal plants of Jordan: Scoping review
    • Authors: Abu-Odeh, A., Fino, L., Al-Absi, G., Shehadeh, M., Suaifan, G.
    • Year: 2023
    • Journal: Heliyon, Volume 9, Issue 6, Article e17081
  8. Antibiotic—Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy
    • Authors: Suaifan, G.A.R.Y., Abdel Rahman, D.M.A., Abu-Odeh, A.M., Shehadeh, M.B., Darwish, R.M.
    • Year: 2023
    • Journal: PLoS ONE, Volume 18, Issue 3, Article e0282705
  9. Knowledge, practice and attitude associated with SARS-CoV-2 Delta Variant among adults in Jordan
    • Authors: Suaifan, G.A.R.Y., Abu-Odeh, A.M., Shehadeh, M.B., Shahwan, M., Jbara, F.A.
    • Year: 2022
    • Journal: PLoS ONE, Volume 17, Issue 12, Article e0278243